[VectraCor Inc.] announced 510(k) clearance to market its noninvasive VectraplexECG system with VectraplexAMI technology March 23. It is the only stand-alone cardiac monitor/electrocardiogram with an electrical biomarker for the real-time detection of ECG changes that may be indicative of an acute myocardial infarction, plus the capability to derive a 15-lead ECG, the company said, unveiling the product at the American College of Cardiology meeting in Chicago. The company claims the system allows for faster treatment than conventional ECG AMI detection, which can take up to 24 hours and involve the placement of 10 electrodes with invasive blood draws every 4-6 hours. “The VectraplexECG system uses only five electrodes to detect ECG changes suggestive of AMI and derive a 15-lead ECG,” the firm said.
The X Series monitor/defibrillator for mobile EMS use gained 510(k) clearance, Zoll Medical Corp. announced March 22. At less than 12 pounds, it is about half the size and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?